 |
|
| Blog results | Results 1 - 10 of about 182 for cancer ovarian telcyta. (0.19 seconds) |
| Sorted by relevance Sort by date |
| 5 Oct 2009 by Jason Ramsey The results are very important for the company since it is pursuing corporate partners to help in the further development of Telcyta which has been in multiple Phase 2 and Phase 3 trials for other cancers including ovarian cancer and ... TopNews United States - http://topnews.us/ |
| 1 Oct 2009 ... a modified glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA, a tumor-activated prodrug for the treatment of advanced ovarian cancer and non-small cell lung cancer. ... Drugs.com - Clinical Trials - http://www.drugs.com/clinical_trials.html [ More results from Drugs.com - Clinical Trials ] |
| 30 Aug 2009 by Michael Becker ... share – in late December 2006 after the company reported that its most advanced development compound, Telcyta® (canfosfamide HCI), failed to improve survival in patients with advanced lung cancer or in patients with ovarian cancer. ... MD Becker Partners LLC: Blog Site - http://mdbpartners.wordpress.com/ |
| 31 May 2009 by Sandi Pniauskas telik presents results at asco from assist-5 trial of telcyta in platinum refractory and resistant ovarian cancer. ovarian+cancer. technorati blog finder meta name="y_key" content="4bf70d7d255e2449" OVARIAN CANCER and US - http://ovariancancerandus.blogspot.com/ [ More results from OVARIAN CANCER and US ] |
| 4 Jun 2007 The FDA has ordered Telik to halt studies of Telcyta after the developer released data over the weekend that showed women taking the experimental ovarian cancer drug died on average five months faster than women in a control group. News - http://www.fiercebiotech.com/news |
| 18 Jun 2009 by Paul Cacciatore Telik Presents Results At ASCO From ASSIST-5 Trial of TELCYTA in Platinum Refractory And Resistant Ovarian Cancer, News & Events, Telik, Inc., May 31, 2009. Two Studies Provide Contradictory Data for Use of Carboplatin + Pegylated ... Libby's H*O*P*E* (*Helping *Ovarian Cancer... - http://healthinfoispower.wordpress.com/ |
| 26 Dec 2006 by C.A. Morrison reuters reports that the experimental drug telcyta has not increased the survival rate for patients with stage iii ovarian or lung cancer. the drug is made by telik, inc.. PAXALLES - http://paxalles.blogs.com/paxalles/ |
| 15 Oct 2007 by 24/7 Wall St. This is Telik's most advanced development program, a tumor-activated small molecule product candidate in clinical development for the treatment of advanced ovarian cancer and non- small cell lung cancer. Its other development candidate ... 24/7 Wall St. - http://www.247wallst.com/ [ More results from 24/7 Wall St. ] |
| 12 Jun 2009 by Cancercompass News: top stories pld alone in second-line therapy in platinum refractory or resistant ovarian cancer. study design: patients with platinum refractory or resistant ovarian cancer (platinum refractory, primary platinum resistant, secondary platinum ... Cancer Free Success Team - http://www.cancerfreesuccessteam.com/ |
| 21 Oct 2009 by sam1933 TELCYTA® (Canfosfamide HCl) A cancer cell-activated small molecule that is in development for ovarian and non-small cell lung cancer. Preclinical Pipeline Additional potential product candidates in our pipeline have resulted from our ... SocialPicks.com: Recent Picks - http://www.socialpicks.com/ |
Stay up to date on these results:
| Google Home - About Google Blog Search Beta - Information for Blog Authors |
